Teva Ordered Again To Delist Inhaler Patents From The Orange Book. But Is This The End?

The US FTC Celebrated The Decision, Which May Affect Other Combination Products

The fight between Teva and Amneal over the ProAir HFA inhaler has reached another milestone, with the appellate court affirming the previous ruling to delist five patents from the FDA’s Orange Book. However, Teva might not be backing down.

Two inhalers on a blue background
(Shutterstock)

Teva was hit by another legal blow in the ongoing inhaler patent infringement saga with Amneal after an appellate court supported a previous ruling.

On 20 December, the US Court of Appeals for the Federal Circuit affirmed a lower district court decision, which was announced in June, ordering the Israeli firm to delist...

More from Legal & IP

More from Generics Bulletin